A Phase 3 interventional study of Cetirizine Dry Syrup in Pruritus, sponsored by GlaxoSmithKline. Completed at 1 site. Open to participants aged 2 Years to 14 Years. Per ClinicalTrials.gov, last updated 2013-05-06.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
To assess the safety of long-term use of cetirizine dry syrup in children with various type of cutaneous disease accompanied on pruritus.
354 studies on the registry are indexed under Pruritus; 74 are open to participants now.
This study's enrollment of 60 is close to the median of 60 across 294 interventional studies indexed under Pruritus.
Browse Pruritus studies →GlaxoSmithKline is the lead sponsor of 3,562 studies on the registry; 117 are open to participants now.
Of its 258 completed or terminated interventional studies of FDA-regulated products, 232 (90%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion criteria:
To assess the safety
-severity of pruritus -total pruritus score -daily main prurutus score -Severity of eruption -Patient global Improvement rating -Body temperature -Adverse events -Cetirizine serum concentrations
This study is completed, as verified in May 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
GlaxoSmithKline